

# Michael J Rybak

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/10691076/michael-j-rybak-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218  
papers

16,724  
citations

65  
h-index

124  
g-index

221  
ext. papers

19,139  
ext. citations

6.1  
avg. IF

6.64  
L-index

#	Paper	IF	Citations
218	Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, e18-55	11.6	1736
217	Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. <i>Circulation</i> , <b>2015</b> , 132, 1435-86	16.7	1479
216	Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children: executive summary. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, 285-92	11.6	1209
215	Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 325-7	11.6	566
214	The pharmacokinetic and pharmacodynamic properties of vancomycin. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42 Suppl 1, S35-9	11.6	483
213	Outcomes analysis of delayed antibiotic treatment for hospital-acquired <i>Staphylococcus aureus</i> bacteremia. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 36, 1418-23	11.6	474
212	Impact of vancomycin exposure on outcomes in patients with methicillin-resistant <i>Staphylococcus aureus</i> bacteremia: support for consensus guidelines suggested targets. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, 975-81	11.6	356
211	Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1999</b> , 43, 1549-55	5.9	324
210	Nephrotoxicity of vancomycin, alone and with an aminoglycoside. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1990</b> , 25, 679-87	5.1	317
209	Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> , <b>2011</b> , 68, 853-864	2.2	307
208	In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against <i>Staphylococci</i> and <i>Enterococci</i> , including vancomycin-intermediate and -resistant strains. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 1062-6	5.9	275
207	Impact of high-inoculum <i>Staphylococcus aureus</i> on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2004</b> , 48, 4665-72	5.9	240
206	Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 1275-9	5.8	207
205	Pharmacodynamics of cefepime in patients with Gram-negative infections. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2002</b> , 50, 425-8	5.1	180
204	Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant <i>Staphylococcus aureus</i> , vancomycin-resistant <i>Enterococcus faecium</i> , and methicillin-resistant <i>Staphylococcus aureus</i> isolates in an in vitro pharmacodynamic model with simulated clinical concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2001</b> , 45, 1512-8	5.9	166
203	The importance of bactericidal drugs: future directions in infectious disease. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 1314-20	11.6	153
202	Ceragenins: cholic acid-based mimics of antimicrobial peptides. <i>Accounts of Chemical Research</i> , <b>2008</b> , 41, 1233-40	24.3	138

201	Early use of daptomycin versus vancomycin for methicillin-resistant <i>Staphylococcus aureus</i> bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 1562-9	11.6	134
200	A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	126
199	Characterization of vancomycin-heteroresistant <i>Staphylococcus aureus</i> from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). <i>Journal of Clinical Microbiology</i> , <b>2008</b> , 46, 2958-4	8.7	120
198	Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 1317-33	3.5	118
197	Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperzolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against <i>Staphylococcus aureus</i> , coagulase-negative staphylococci, <i>Enterococcus faecalis</i> , and <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>1998</b> , 42, 721-4	5.9	118
196	Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, 922-9	11.6	117
195	Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , <b>2006</b> , 58, 338-43	5.1	115
194	Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, 116-123	11.6	114
193	High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. <i>Pharmacotherapy</i> , <b>2011</b> , 31, 527-36	5.8	112
192	Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant <i>Staphylococcus aureus</i> isolates collected in nine U.S. medical centers from 2002 to 2006. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 4127-32	5.9	108
191	Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant <i>Staphylococcus aureus</i> isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 200, 1355-66	7	107
190	Comparison of length of hospital stay for patients with known or suspected methicillin-resistant <i>Staphylococcus</i> species infections treated with linezolid or vancomycin: a randomized, multicenter trial. <i>Pharmacotherapy</i> , <b>2001</b> , 21, 263-74	5.8	102
189	Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>1999</b> , 43, 335-40	5.9	101
188	Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate <i>Staphylococcus aureus</i> in a pharmacokinetic/pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 66-73	5.9	98
187	Short-course gentamicin in combination with daptomycin or vancomycin against <i>Staphylococcus aureus</i> in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 2735-45	5.9	96
186	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of <i>Staphylococcus aureus</i> biofilm. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 4329-34	5.9	95
185	A Review of Combination Antimicrobial Therapy for <i>Enterococcus faecalis</i> Bloodstream Infections and Infective Endocarditis. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 303-309	11.6	92
184	Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant <i>Staphylococcus aureus</i> . <i>Infection Control and Hospital Epidemiology</i> , <b>2006</b> , 27, 1025-31	3	92

183	Epidemiology, treatment, and outcomes of nosocomial bacteremic <i>Staphylococcus aureus</i> pneumonia. <i>Chest</i> , <b>2005</b> , 128, 1414-22	5.3	91
182	Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 1853-61	5.9	90
181	Antimicrobial activities of ceragenins against clinical isolates of resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 1268-73	5.9	89
180	Community-associated methicillin-resistant <i>Staphylococcus aureus</i> : a review. <i>Pharmacotherapy</i> , <b>2005</b> , 25, 74-85	5.8	89
179	Daptomycin dose-effect relationship against resistant gram-positive organisms. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 1598-603	5.9	87
178	Community- and health care-associated methicillin-resistant <i>Staphylococcus aureus</i> : a comparison of molecular epidemiology and antimicrobial activities of various agents. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2007</b> , 58, 41-7	2.9	86
177	Emergence of methicillin-resistant <i>Staphylococcus aureus</i> with intermediate glycopeptide resistance: clinical significance and treatment options. <i>Drugs</i> , <b>2001</b> , 61, 1-7	12.1	85
176	Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 2541-6	5.9	84
175	Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3731-3	5.9	83
174	Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. <i>Drugs</i> , <b>1996</b> , 52, 390-405	12.1	82
173	Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. <i>Pharmacotherapy</i> , <b>1999</b> , 19, 1252-60	5.8	79
172	Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against <i>Staphylococcus aureus</i> isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 2061-7	5.9	78
171	Daptomycin. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 41-57	5.8	78
170	Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant <i>Staphylococcus aureus</i> with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 2151-9	5.9	77
169	Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant <i>Enterococcus</i> isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 3174-80	5.9	76
168	Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 1089-91	5.9	76
167	β-lactam combinations with daptomycin provide synergy against vancomycin-resistant <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> . <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 1738-43	5.1	75
166	A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 2921-6	5.1	75

165	Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	72
164	Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. <i>Journal of Emergency Medicine</i> , <b>2015</b> , 48, 508-19	1.5	72
163	Multicenter study of high-dose daptomycin for treatment of enterococcal infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 4190-6	5.9	72
162	Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , <b>2013</b> , 42, 202-10	14.3	71
161	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 831-6	5.9	70
160	Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 1752-5	5.9	70
159	In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 4712-7	5.9	69
158	Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2003</b> , 13, 2109-12	2.9	69
157	Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. <i>Pharmacotherapy</i> , <b>2012</b> , 32, 195-201	5.8	68
156	Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 60, 334-40	5.1	66
155	Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 365-70	5.1	65
154	Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 3960-3	5.9	65
153	In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 2606-12	5.9	65
152	Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 1242-1250	11.6	64
151	Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. <i>Journal of Clinical Microbiology</i> , <b>2008</b> , 46, 2890-6	9.7	64
150	Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. <i>Surgical Infections</i> , <b>2003</b> , 4, 57-70	2	64
149	In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 1925-9	5.9	64
148	Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. <i>Pharmacotherapy</i> , <b>2007</b> , 27, 1611-8	5.8	63

147	Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. <i>Pharmacotherapy</i> , <b>1999</b> , 19, 257-66	5.8	63
146	Inhibition of drug metabolism by quinolone antibiotics. <i>Clinical Pharmacokinetics</i> , <b>1988</b> , 15, 194-204	6.2	62
145	Evaluation of the Etest GRD for the detection of <i>Staphylococcus aureus</i> with reduced susceptibility to glycopeptides. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 489-92	5.1	59
144	Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 4252-4259	5.9	58
143	Evaluation of vancomycin susceptibility testing for methicillin-resistant <i>Staphylococcus aureus</i> : comparison of Etest and three automated testing methods. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 2077-81	9.7	58
142	Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against <i>Staphylococcus aureus</i> and <i>S. epidermidis</i> in a Novel In Vitro PK/PD Model of Bacterial Biofilm. <i>Infectious Diseases and Therapy</i> , <b>2014</b> , 4, 51	6.2	55
141	Daptomycin - a novel antibiotic against Gram-positive pathogens. <i>Expert Opinion on Pharmacotherapy</i> , <b>2004</b> , 5, 2321-31	4	55
140	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1361-1364	11.6	55
139	Pharmacodynamics: relation to antimicrobial resistance. <i>American Journal of Medicine</i> , <b>2006</b> , 119, S37-44; discussion S62-70	2.4	53
138	Making the change to area under the curve-based vancomycin dosing. <i>American Journal of Health-System Pharmacy</i> , <b>2018</b> , 75, 1986-1995	2.2	53
137	Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. <i>Infectious Diseases and Therapy</i> , <b>2014</b> , 3, 35-43	6.2	52
136	Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against <i>Streptococcus pneumoniae</i> in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 2606-14	5.9	51
135	Role of Combination Antimicrobial Therapy for Vancomycin-Resistant <i>Enterococcus faecium</i> Infections: Review of the Current Evidence. <i>Pharmacotherapy</i> , <b>2017</b> , 37, 579-592	5.8	50
134	Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 3505-9	5.9	50
133	Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant <i>Staphylococcus aureus</i> in an in vitro model of simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 5187-92	5.9	50
132	Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among <i>Staphylococcus aureus</i> causing bloodstream infections in nine USA hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 64, 1024-8	5.1	50
131	Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate <i>Staphylococcus aureus</i> by time-kill curve methods. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1999</b> , 43, 717-21	5.9	50
130	Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2003</b> , 47, 539-46	2.9	49

129	Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect". <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 2664-8	5.9	48
128	Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2003</b> , 13, 1745-9	2.9	48
127	Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. <i>Annals of Pharmacotherapy</i> , <b>1995</b> , 29, 1022-7	2.9	48
126	Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 2978-85	5.9	47
125	Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 1256-63	5.8	47
124	Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3743-50	5.9	47
123	Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 2148-54	5.1	45
122	Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the "seesaw effect": Taking advantage of the back door left open?. <i>Drug Resistance Updates</i> , <b>2013</b> , 16, 73-9	23.2	43
121	Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	41
120	Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. <i>Journal of Clinical Microbiology</i> , <b>2008</b> , 46, 220-4	9.7	41
119	Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1998</b> , 42, 2710-7	5.9	40
118	Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1999</b> , 43, 1914-8	5.9	40
117	Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2001</b> , 45, 1654-9	5.9	39
116	Daptomycin Plus $\beta$ -Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1-10	11.6	39
115	Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 5841-8	5.9	38
114	Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2004</b> , 54, 259-62	5.1	38
113	In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. <i>International Journal of Antimicrobial Agents</i> , <b>2004</b> , 24, 150-60	14.3	38
112	Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. <i>Pharmacotherapy</i> , <b>2008</b> , 28, 458-68	5.8	37

111	Potent synergy of ceftobiprole plus daptomycin against multiple strains of <i>Staphylococcus aureus</i> with various resistance phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 3006-10	5.1	36
110	Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant <i>Staphylococcus aureus</i> in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3177-81	5.9	35
109	Current and prospective treatments for multidrug-resistant gram-positive infections. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 1919-32	4	35
108	Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Infectious Diseases</i> , <b>2013</b> , 208, 67-74	7	35
107	Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 311-3	5.1	34
106	Treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections with a minimal inhibitory concentration of 2 µg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. <i>Annals of Pharmacotherapy</i> , <b>2012</b> , 46, 1587-97	2.9	34
105	Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. <i>Pharmacotherapy</i> , <b>2015</b> , 35, 935-48	5.8	33
104	Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2004</b> , 50, 125-30	2.9	33
103	β-Lactams enhance daptomycin activity against vancomycin-resistant <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> in in vitro pharmacokinetic/pharmacodynamic models. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 2842-8	5.9	32
102	Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant <i>Staphylococcus aureus</i> strains in an in vitro pharmacokinetic/pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 3522-6	5.9	32
101	Resistance to antimicrobial agents: an update. <i>Pharmacotherapy</i> , <b>2004</b> , 24, 203S-15S	5.8	32
100	Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 1921-4	5.9	32
99	Ofloxacin clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , <b>1992</b> , 22, 32-46	6.2	31
98	The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 505-9	5.1	30
97	β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible <i>Staphylococcus aureus</i> , Vancomycin-Intermediate <i>S. aureus</i> (VISA), and Heterogeneous VISA. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	30
96	Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant <i>Staphylococcus aureus</i> bacteremia. <i>Pharmacotherapy</i> , <b>2013</b> , 33, 3-10	5.8	30
95	The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of <i>Staphylococcus aureus</i> in an in-vitro infection model. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1999</b> , 44, 343-9	5.1	30
94	Multicenter Cohort of Patients With Methicillin-Resistant Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofz538	1	30



93	Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 4497-503	5.9	29
92	A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 2989-92	5.9	29
91	Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2008</b> , 60, 441-4	2.9	29
90	Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2005</b> , 49, 302-8	5.9	29
89	Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 805-7	5.9	28
88	Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 5700-11	5.9	28
87	Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 1969-76	5.9	27
86	Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 5716-23	5.9	27
85	Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 59, 1190-3	5.1	27
84	Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 5990-3	5.9	26
83	Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 1315-20	5.9	26
82	Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2006</b> , 57, 116-21	5.1	25
81	Increased theophylline concentrations secondary to ciprofloxacin. <i>Drug Intelligence &amp; Clinical Pharmacy</i> , <b>1987</b> , 21, 879-81		25
80	Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 1708-16	5.9	24
79	Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 155-60	5.1	23
78	Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus. <i>Pharmacotherapy</i> , <b>2007</b> , 27, 3-10	5.8	23
77	Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2928-33	5.9	22
76	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1650-1657	11.6	22

75	In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired methicillin-resistant <i>Staphylococcus aureus</i> (HA-MRSA) isolates. <i>International Journal of Antimicrobial Agents</i> , <b>2010</b> , 35, 527-30	14.3	21
74	Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 489-498	5.1	21
73	High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. <i>Current Infectious Disease Reports</i> , <b>2014</b> , 16, 429	3.9	20
72	Growing prevalence of vancomycin-resistant <i>Enterococcus faecalis</i> in the region with the highest prevalence of vancomycin-resistant <i>Staphylococcus aureus</i> . <i>Infection Control and Hospital Epidemiology</i> , <b>2011</b> , 32, 922-4	2	20
71	Accessory gene regulator dysfunction: an advantage for <i>Staphylococcus aureus</i> in health-care settings?. <i>Journal of Infectious Diseases</i> , <b>2009</b> , 199, 1558-9	7	20
70	Oritavancin Combinations with $\beta$ -Lactams against Multidrug-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant Enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 2352-8	5.9	19
69	Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible <i>Staphylococcus aureus</i> in an in vitro pharmacokinetic/pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 955-9	5.9	19
68	Clinical isolates of <i>Staphylococcus aureus</i> from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2005</b> , 51, 119-23 <sup>9</sup>	2.9	19
67	Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1986</b> , 17, 115-20	5.1	18
66	Characterizing vancomycin-resistant <i>Enterococcus</i> strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 4748-54	5.9	17
65	Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 1305-10	5.1	17
64	Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in <i>Staphylococcus aureus</i> : Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 60, 1584-91	5.9	16
63	Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with $\beta$ -Lactams against Daptomycin-Susceptible <i>Enterococcus faecium</i> Harboring LiaSR Substitutions. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	16
62	Nephrotoxicity comparison of two commercially available generic vancomycin products. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 5470-4	5.9	15
61	Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of in a Simulated Pharmacodynamic/Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	14
60	Impact of <i>Enterococcus faecalis</i> on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant <i>Staphylococcus aureus</i> in a mixed-pathogen pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 1298-303	5.9	14
59	Once-daily aminoglycoside in the treatment of <i>Enterococcus faecalis</i> endocarditis: case report and review. <i>Pharmacotherapy</i> , <b>2000</b> , 20, 1116-9	5.8	14
58	Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible <i>Staphylococcus aureus</i> in an In Vitro, Hollow-Fiber Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3970-5	5.9	14

57	Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs). <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 2290-2296	5.1	13
56	Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with $\beta$ -Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis. <i>Infectious Diseases and Therapy</i> , <b>2020</b> , 9, 325-339	6.2	13
55	Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	12
54	Classical $\beta$ -Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	12
53	Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated methicillin-resistant Staphylococcus aureus. <i>International Journal of Antimicrobial Agents</i> , <b>2010</b> , 35, 25-9	14.3	12
52	Impact of dose de-escalation and escalation on daptomycin $\phi$ pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 2160-5	5.9	12
51	Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis. <i>Pharmacotherapy</i> , <b>2020</b> , 40, 648-658	5.8	11
50	A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. <i>Infectious Diseases and Therapy</i> , <b>2020</b> , 9, 89-106	6.2	11
49	Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an Model of Simulated Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	11
48	Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 4636-41	5.9	11
47	In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2004</b> , 48, 2719-23	5.9	11
46	Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 1984-7	5.9	10
45	Evaluation of dalbavancin alone and in combination with $\beta$ -lactam antibiotics against resistant phenotypes of Staphylococcus aureus. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 82-86	5.1	10
44	Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2018</b> , 91, 363-370	2.9	10
43	Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin Susceptibilities. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	9
42	In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. <i>International Journal of Antimicrobial Agents</i> , <b>2011</b> , 38, 301-6	14.3	9
41	Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2006</b> , 54, 305-310	3.0	9
40	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz079	1	8

39	Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury. <i>Infectious Diseases and Therapy</i> , <b>2015</b> , 4, 519-28	6.2	8
38	Therapeutic options for Gram-positive infections. <i>Journal of Hospital Infection</i> , <b>2001</b> , 49 Suppl A, S25-32	6.9	8
37	The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA-Salvaging the Gold Standards with Combination Therapy. <i>Antibiotics</i> , <b>2020</b> , 9,	4.9	8
36	Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of in a Pharmacokinetic/Pharmacodynamic Model. <i>Antibiotics</i> , <b>2020</b> , 9,	4.9	7
35	Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against <i>Pseudomonas aeruginosa</i> , <i>Escherichia coli</i> and Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infectious Diseases and Therapy</i> , <b>2016</b> , 5, 367-77	6.2	7
34	Evaluation of Daptomycin Non-Susceptible <i>Staphylococcus aureus</i> for Stability, Population Profiles, <i>mprF</i> Mutations, and Daptomycin Activity. <i>Infectious Diseases and Therapy</i> , <b>2013</b> , 2, 187-200	6.2	7
33	$\beta$ -Lactamase Inhibitors Enhance the Synergy between $\beta$ -Lactam Antibiotics and Daptomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	7
32	Comparative epidemiology of bacteremia due to methicillin-resistant <i>Staphylococcus aureus</i> between older and younger adults: a propensity score analysis. <i>Infection Control and Hospital Epidemiology</i> , <b>2013</b> , 34, 400-6	2	7
31	Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant <i>Staphylococcus aureus</i> isolates from cancer patients. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2017</b> , 87, 338-342	2.9	6
30	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz077	1	6
29	Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant <i>Staphylococcus aureus</i> Infections. <i>Infectious Diseases and Therapy</i> , <b>2018</b> , 7, 161-169	6.2	6
28	Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated. <i>Infectious Diseases and Therapy</i> , <b>2019</b> , 8, 627-640	6.2	6
27	Impact of Daptomycin Dose Exposure Alone or in Combination with $\beta$ -Lactams or Rifampin against Vancomycin-Resistant Enterococci in an Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	6
26	Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infectious Diseases and Therapy</i> , <b>2019</b> , 8, 199-208	6.2	5
25	Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against <i>Streptococcus mitis</i> in an Simulated Endocarditis Vegetation Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	5
24	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 54, 346-350	14.3	5
23	Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria. <i>Expert Opinion on Emerging Drugs</i> , <b>2001</b> , 6, 43-55		5
22	Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 65,	5.9	5

21	Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	5
20	A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2020</b> , 39, 2199-2203	5.3	4
19	Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function. <i>Pharmacotherapy</i> , <b>2000</b> , 20, 554-61	5.8	4
18	Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e4560-e4567	11.6	4
17	Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection versus illusion?. <i>American Journal of Infection Control</i> , <b>2016</b> , 44, 47-9	3.8	3
16	Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. <i>Journal of Clinical Microbiology</i> , <b>2008</b> , 46, 2471; author reply 2471-2	9.7	3
15	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant. <i>Pharmaceutics</i> , <b>2021</b> , 13,	6.4	3
14	Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections. <i>Infectious Diseases and Therapy</i> , <b>2019</b> , 8, 229-242	6.2	3
13	Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients. <i>Journal of Global Antimicrobial Resistance</i> , <b>2019</b> , 17, 16-18	3.4	2
12	A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2019</b> , 38, 843-850	5.3	2
11	Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus $\beta$ -Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 1531-1539	5.7	2
10	Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Bacteremia: STAPH Study. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab261	1	2
9	Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting. <i>Infectious Diseases and Therapy</i> , <b>2018</b> , 7, 495-507	6.2	2
8	Reply to Koehler et al. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 901-902	11.6	1
7	Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 1272-3	5.1	1
6	Validity of 2020 vancomycin consensus recommendations and further guidance for practical application. <i>American Journal of Health-System Pharmacy</i> , <b>2021</b> , 78, 1364-1367	2.2	1
5	Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study. <i>Infectious Diseases and Therapy</i> , <b>2019</b> , 8, 75-85	6.2	1
4	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Bloodstream Infection.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofab606	1	1

3 Daptomycin: Pharmacokinetic, Pharmacodynamic, and Dose Optimization **2014**, 381-399

2 Reply to Cataldo et al. *Clinical Infectious Diseases*, **2011**, 53, 310-310

11.6

1 Daptomycin Resistance **2017**, 307-317